Research Article

Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B

Table 2

Virological, biochemical, and clinical response after low-dose TDF in overall population, viraemic, and nonviraemic patients at baseline.

Variables3 months, (%)6 months, (%)12 months, (%)

Overall response ()
 CVR36 (80)41 (91.1)43 (95.6)
 PVR (ADN-VHB 20–2000 UI/mL)5 (11.1)3 (6.7)2 (4.4)
 UI/mL4 (8.9)1 (2.2)0 (0)
 ALT normalization29 (64.4)39 (86.7)45 (100)
 HCC development0 (0)0 (0)0 (0)
 Decompensation of cirrhosis ()0 (0)0 (0)0 (0)
Viraemic patients at baseline ()
 CVR26/35 (74.3)31/35 (88.6)33/35 (94.3)
 PVR (ADN-VHB 20–2000 UI/mL)5/35 (14.3)3/35 (8.6)2/35 (5.7)
 UI/mL4/35 (11.4)1/35 (2.8)0/35 (0)
Nonviraemic patients at baseline ()
 CVR10/10 (100)10/10 (100)10/10 (100)
Elevated ALT at baseline ()
 ALT normalization0/16 (0)10/16 (62.5)16/16 (100)

CVR: complete virological response; PVR: partial virological response; DNA: deoxyribonucleic acid; HBV: hepatitis B virus; ALT: alanine aminotransferase; HCC: hepatocellular carcinoma.